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Objective: To illustrate an approach to compare CD4 cell count
and HIV-RNA monitoring strategies in HIV-positive individuals on
antiretroviral therapy (ART).
Design: Prospective studies of HIV-positive individuals in Europe
and the USA in the HIV-CAUSAL Collaboration and The Center for
AIDS Research Network of Integrated Clinical Systems.
Methods: Antiretroviral-naive individuals who initiated ART and
became virologically suppressed within 12 months were followed
from the date of suppression. We compared 3 CD4 cell count and
HIV-RNA monitoring strategies: once every (1) 3 6 1 months, (2)
6 6 1 months, and (3) 9–12 6 1 months. We used inverse-
probability weighted models to compare these strategies with respect
to clinical, immunologic, and virologic outcomes.
Results: In 39,029 eligible individuals, there were 265 deaths and
690 AIDS-defining illnesses or deaths. Compared with the 3-month
strategy, the mortality hazard ratios (95% CIs) were 0.86 (0.42 to
1.78) for the 6 months and 0.82 (0.46 to 1.47) for the 9–12 month
strategy. The respective 18-month risk ratios (95% CIs) of virologic
failure (RNA .200) were 0.74 (0.46 to 1.19) and 2.35 (1.56 to 3.54)
and 18-month mean CD4 differences (95% CIs) were 25.3 (218.6
to 7.9) and 231.7 (252.0 to 211.3). The estimates for the 2-year
risk of AIDS-defining illness or death were similar across strategies.
Conclusions: Our findings suggest that monitoring frequency of
virologically suppressed individuals can be decreased from every
3 months to every 6, 9, or 12 months with respect to clinical outcomes.
Because effects of different monitoring strategies could take years to
materialize, longer follow-up is needed to fully evaluate this question.
Key Words: HIV, CD4 cell count, HIV RNA, monitoring,
observational studies, mortality
(J Acquir Immune Defic Syndr 2016;72:214–221)
INTRODUCTION
The benefits of immunologic and virologic monitoring
for the management of HIV-positive individuals are well
established.1–6 However, the optimal frequency with which
CD4 cell count and HIV RNA should be monitored remains
unknown. More frequent monitoring strategies are costly and
put an increased burden on the patient and health systems.
Still, less frequent monitoring could lead to delays in
detecting when individuals should switch treatment regimens
or initiate prophylaxis for opportunistic infections, eventually
resulting in an increase in development of resistant virus,
morbidity, and mortality.7–9
One US trial randomized individuals with CD4 cell
count $250 cells per microliter and undetectable viral load to
either CD4 cell count and HIV RNA monitoring every
4 months or every 6 months. The trial found no differences
in virologic failure after 24 months on antiretroviral therapy
(ART), but did not assess clinical endpoints.10 Observational
studies comparing monitoring strategies after cART initiation
have also not assessed clinical endpoints, have had short
follow-up, and have not compared monitoring strategies
within important subgroups, such as individuals with low
CD4 cell counts, or with different monitoring schedules
during episodes of viral rebound.9,11–13
As a result of the sparse evidence, clinical guidelines in
high-income countries vary.14–17 The European AIDS Clinical
Society recommends monitoring CD4 cell count every 3–6
months after cART initiation, with less frequent monitoring
(every 6–12 months) for stable persons with a CD4 cell count
.350 cells per microliter and an undetectable viral load (HIV
RNA ,50 copies/mL). HIV RNA should be monitored
frequently (more than once every 3 months) following cART
initiation and every 3–6 months thereafter.15 In comparison,
the Department of Health and Human Services advises
monitoring CD4 cell count every 3–6 months after cART
initiation, with a decrease in monitoring frequency to every
12 months among individuals with an undetectable viral load
(HIV RNA #200 copies/mL) and CD4 cell counts between
300 and 500 cells per microliter for at least 2 years. HIV RNA
should be monitored every 1–2 months following cART
initiation and every 3–4 months once the level falls below the
assay’s limit of detection; the interval may be extended to
every 6 months among stable individuals virologically sup-
pressed for more than 2 years.14
In the absence of large randomized trials to determine
the optimal CD4 cell count and HIV RNA monitoring
frequency, observational data need to be used to inform
clinical decisions. An advantage of using observational data is
that multiple strategies can be compared simultaneously. In
this study, we illustrate how cohort studies can be used to
estimate the effect of CD4 cell count and HIV RNA
monitoring strategies on clinical, virologic, and immunologic
outcomes in virologically suppressed HIV-positive patients.
We use observational data from 2 collaborations of pro-
spective cohort studies from high-income countries.
METHODS
Study Population
The HIV-CAUSAL Collaboration includes prospective
cohort studies from 6 European countries and the United
States.18 The individual cohort studies are FHDH-ANRSC04
(France), ANRS PRIMO (France), ANRS SEROCO (France),
ANRS CO3-Aquitaine (France), UK CHIC (United King-
dom), UK Register of HIV Seroconverts (United Kingdom),
ATHENA (the Netherlands), SHCS (Switzerland), PISCIS
(Spain), CoRIS/CoRIS-MD (Spain), GEMES (Spain), VACS
(United States), and AMACS (Greece). The Center for AIDS
Research (CFAR) Network of Integrated Clinical Systems
(CNICS) integrates clinical data from inpatient and outpatient
encounters of HIV-positive individuals at 8 US sites: Case
Western Reserve University, Fenway Community Health
Clinic, Johns Hopkins University, University of Alabama at
Birmingham, University of California at San Diego, Univer-
sity of California at San Francisco, University of North
Carolina, and University of Washington.19 All cohorts
included in the HIV-CAUSAL and CNICS Collaborations
were assembled prospectively and are based on data collected
for clinical purposes. Each cohort in the collaborations
collected data prospectively, including all CD4 cell counts,
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HIV RNA measurements, treatment initiations, deaths, and
AIDS-defining illnesses. Monitoring protocols were not
standardized in any of the cohorts.
Our analysis was restricted to antiretroviral-therapy
naïve individuals18 who initiated a cART regimen in 2000
or later consisting of at least 2 nucleoside reverse transcriptase
inhibitors plus one or more of the following: protease
inhibitor, non-nucleoside reverse transcriptase inhibitor,
entry/fusion inhibitor, or integrase inhibitor. Individuals with
confirmed virologic suppression (2 consecutive HIV RNA
#200 copies/mL) within 12 months of initiating cART were
eligible for inclusion in our study. Baseline was defined as the
date of confirmed virologic suppression following cART
initiation. Our analysis was further restricted to individuals
who met the following criteria at baseline: age 18 years or
older, no pregnancy (when information was available), no
history of AIDS (defined as the onset of any Category C
AIDS-defining illness),20 and a CD4 cell count within the
previous 3 months (see Table S1, Supplemental Digital
Content, http://links.lww.com/QAI/A794).
Outcomes
We considered 2 clinical outcomes: all-cause mortality
and a combined end point of AIDS-defining illness or death.
The date of death was identified using a combination of national
and local mortality registries and clinical records, as described
elsewhere,18,19 and AIDS-defining illnesses were ascertained by
the treating physicians. For each individual, follow-up ended at
the event of interest, pregnancy (if known), the cohort-specific
administrative end of follow-up, or 24 months of follow-up,
whichever occurred earlier. We also considered virologic failure
(HIV RNA.200 copies/mL) at 186 2 months and mean CD4
cell count over the first 18 months of follow-up as outcomes.
Monitoring Strategies
We compared 3 monitoring strategies: monitor CD4
cell count and HIV RNA once every (1) 3 6 1 months, (2)
66 1 months, and (3) 9–126 1 months. No restrictions were
placed on monitoring frequency before baseline. Over the
study follow-up, monitoring once every 36 1 was required in
all strategies during periods of virologic rebound (HIV RNA
.200 copies/mL) or low CD4 cell counts (#200 cells/mL)
and after diagnosis of an AIDS-defining illness. In the
approximately 1% of months during which more than one
CD4 cell count measurement was recorded, we disregarded
all but the last CD4 cell count measurement recorded in that
month. The same procedure was used for HIV RNA.
At baseline, all individuals included in our study had
data consistent with all 3 monitoring strategies by design.
Instead of randomly allocating each individual to 1 of the 3
monitoring strategies, we created an expanded dataset by
making 3 exact replicates of each individual (1 per strategy).
If and when an individual’s data were no longer consistent
with a given strategy, we artificially censored the correspond-
ing replicate at that time.21,22 Replicates were censored when
they were monitored sooner than indicated by their strategy or
when they were not monitored soon enough. Replicates were
also censored when a CD4 measurement was recorded in
a month without an RNA measurement, or vice versa, which
occurred in 13% of months in which a measurement was
recorded. For example, an individual with CD4 cell count
.200 cells per microliter monitored for the first time after
baseline at the ninth month of follow-up had data consistent
with strategies (1)–(3) until the fourth month of follow-up,
strategies (2)–(3) until the seventh month of follow-up, and
strategy (3) until the ninth month of follow-up (see Figure S1,
Supplemental Digital Content, http://links.lww.com/QAI/
A794). By the 14th month of follow-up, no more than one
replicate per individual with CD4 cell count .200 cells per
microliter will remain uncensored and each individual
remaining in the study will have been monitored at least once.
Statistical Analysis
We conducted all analyses separately for all-cause
mortality and for the combined endpoint of AIDS-defining
illness or death. We fit a pooled logistic regression model to
the expanded dataset to estimate the hazard ratio for
monitoring strategy (a 3-level categorical variable with every
3 6 1 months as the reference) conditional on time of follow-
up (restricted cubic splines with 4 knots at 1, 6, 12, and 24
months) and the following baseline covariates: sex, CD4 cell
count (,200, 200–349, 350–499,$500 cells/mL), years since
HIV diagnosis (,1, 1 to 4, $5 years, unknown), race (white,
black, other or unknown), geographic origin (N. America/W.
Europe, Sub-Saharan Africa, other, unknown), acquisition
group (heterosexual, homosexual or bisexual, injection drug
use, other or unknown), calendar year (restricted cubic splines
with 3 knots at 2001, 2007, and 2011), age (restricted cubic
splines with 3 knots at 25, 39, and 60), cohort, and months
from cART initiation to virologic suppression (2–4, 5–8,$9).
Cut points were chosen based on the distribution of the data.
To adjust for the potential selection bias induced by
censoring,23 we weighted each replicate at each time by the
inverse of the probability of having his or her own
observed monitoring history (see Supplemental Digital
Content, http://links.lww.com/QAI/A794).21 The model for
the weights included the baseline covariates plus time-varying
CD4 cell count, HIV RNA, diagnosis of an AIDS-defining
illness, and monitoring history. The estimated weights were
truncated at the strategy-specific 99th percentile, though
truncation did not materially affect our estimates. Because
our approach relies on the assumption that the model for
monitoring was not misspecified, we confirmed the balance of
baseline CD4 cell count across the monitoring strategies in
the inverse-probability weighted population.
For the outcome virologic failure, we fit a weighted
Poisson regression model with the same covariates as above to
estimate the risk ratio of virologic failure at 18 months for
monitoring strategy among those with measurements at 186 2
months. We used additional inverse-probability weights to
adjust for censoring because of not having a measurement. To
be consistent with the definition of virologic suppression, we
defined virologic failure as HIV RNA .200 copies per
milliliter, but varied this definition in secondary analyses. To
estimate mean CD4 cell count, we fit a weighted log-linear
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regression model for mean CD4 cell count that further included
product (“interaction”) terms between monitoring strategy and
follow-up time (restricted cubic splines with 4 knots at 1, 6, 12,
and 24 months). The model’s predicted values were used to
estimate 18-month mean CD4 cell count curves for each
strategy and the CD4 cell count difference comparing each
strategy to the reference strategy at 18 months.
We also estimated absolute risks for the 2 clinical
outcomes under each of the 3 monitoring strategies. To do so,
we fit a weighted pooled logistic regression model like the
one described above that also included a product term
between monitoring strategy and follow-up time. The model’s
predicted values were used to estimate 18-month survival and
18-month AIDS-free survival curves for each strategy. We
used nonparametric bootstrapping with 500 samples to
compute 95% confidence intervals for all of our estimates.
We explored scenarios under which our estimates may
be biased by unmeasured confounding and performed several
sensitivity analyses to reduce this bias. We (1) excluded
individuals presenting late to care (initiating cART at CD4
cell count ,200 cells/mL); (2) excluded intravenous drug users
and those with an unknown mode of transmission; (3) included
individuals with AIDS at baseline; (4) adjusted for censoring
owing to death for immunologic and virologic outcomes using
inverse-probability weighting; and (5) restricted the analysis to
those initiating cART in 2004 or later. We also additionally
adjusted for the number of months since the last clinic visit in
cohorts for which a CD4 cell count or HIV RNA measurement
could occur at times other than clinic visits and for time since
treatment switching among individuals who switched treatment
after baseline. We excluded large individual cohorts (VACS,
FHDH, and all cohorts included in CNICS) from the analysis to
determine whether the results were driven by one cohort or
collaboration. Finally, we explored alternative definitions of
virologic suppression (eg, HIV RNA #50 copies/mL) and
monitoring strategies that did not change during episodes of
viral rebound, low CD4 cell counts, or after diagnosis of an
AIDS-defining illness, or that required monitoring once every
3–6 months during these times.
RESULTS
Table 1 shows the baseline characteristics of the 39,029
eligible individuals. During follow-up, CD4 cell count and
HIV RNA were measured on average every 3.8 and 3.7
months, respectively. HIV RNA was measured in more than
94% of months in which CD4 cell count was measured and
CD4 cell count was measured in more than 91% of months in
which HIV RNA was measured. In a given month, CD4
monitoring was associated with older age, lower CD4 cell
counts and higher HIV RNA at the previous month, a diagnosis
of an AIDS-defining illness, earlier calendar years, and a history
of more frequent monitoring (see Table S3, Supplemental
Digital Content, http://links.lww.com/QAI/A794). The stron-
gest predictor of monitoring was the number of months since
the last measurement.
Figure 1 shows the number of individuals following
each of the 3 monitoring strategies over time in the all-cause
mortality analysis (the numbers were slightly smaller for the
combined endpoint of AIDS-defining illness or death). Table
2 shows an unadjusted comparison of the 10,525 individuals
who had data consistent with at least one monitoring strategy
for 1 complete year. Individuals monitored every 3 months
had higher baseline CD4 cell counts, became virologically
suppressed earlier after cART initiation, and were less likely
to have initiated cART in 2009 or later, compared with
individuals monitored less frequently. Individuals monitored
every 3 or 6 months were more likely to be virologically
suppressed and had larger changes in mean CD4 cell count
from baseline. Compared with monitoring every 3 months,
TABLE 1. Baseline Characteristics of 39,029 Eligible
Individuals, HIV-CAUSAL Collaboration and CNICS
Baseline Characteristic Persons, % (n)
CD4 cell count, cells/mL
,200 14.7 (5717)
200 to ,350 30.0 (11,704)
350 to ,500 30.0 (11,696)
$500 25.4 (9912)
Mean, value 397
Sex
Male 78.4 (30,601)
Female 21.6 (8428)
Race
White 30.4 (11,881)
Black 15.7 (6114)
Other/unknown 53.9 (21,034)
Age, yrs
,35 34.3 (13,370)
35–50 48.2 (18,806)
.50 17.6 (6853)
Origin
North America or Western Europe 73.2 (28,560)
Sub-Saharan Africa 14.3 (5598)
Other 7.9 (3086)
Unknown 4.6 (1785)
Acquisition group
Heterosexual 33.6 (13,104)
Homo/bisexual 48.9 (19,074)
Injection drug user 4.5 (1747)
Other/unknown 13.1 (5104)
Calendar year
2000–2002 10.8 (4221)
2003–2005 19.7 (7692)
2006–2008 29.2 (11,397)
$2009 40.3 (15,719)
Months to suppression
2–4 35.6 (13,896)
5–8 46.7 (18,243)
9–12 17.7 (6890)
Mean, value 5.9
Years since HIV diagnosis
,1 36.2 (14,124)
1 to ,5 37.6 (14,658)
5 or more 13.0 (5073)
Unknown 13.3 (5174)
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the rate of treatment switching was smaller for 6 months and
for 9–12 months, even after adjusting for baseline and time-
varying confounding, though the 95% confidence intervals
were wide (see Table S4, Supplemental Digital Content,
http://links.lww.com/QAI/A794).
Death and AIDS-Defining Illness
During follow-up, there were 265 deaths and 690 cases
of the combined endpoint of AIDS-defining illness or death.
Each death contributed to a mean of 1.9 strategies and each
case of AIDS-defining illness or death contributed to a mean
of 2.0 strategies. Among those who had an event, the median
(IQR) time to event was 5 (2–9) months for all-cause
mortality and 4 (1–8) months for the combined endpoint of
AIDS-defining illness or death.
Compared with monitoring every 3 months, the overall
mortality hazard ratio (95% CI) was 0.86 (0.42 to 1.78) for 6
months and 0.82 (0.46 to 1.47) for 9–12 months (Table 3).
The corresponding hazard ratios for the combined endpoint of
AIDS-defining illness or death were 0.76 (0.50 to 1.16)
and 1.06 (0.55 to 2.08). If we had not adjusted for time-
varying confounding, the hazard ratio estimates would have
been similar (see Table S5, Supplemental Digital Content,
http://links.lww.com/QAI/A794).
The hazard ratios did not vary substantially by sex,
mode of transmission, or age, but the confidence intervals
were wide. Alternative monitoring strategies resulted in
similar mortality estimates (see Table S6, Supplemental
Digital Content, http://links.lww.com/QAI/A794). None of
the sensitivity analyses described above yielded appreciably
different results (data not shown).
The estimated 18-month survival (95% CI) was 0.99
(0.99 to 1.00) for monitoring once every 3 months, 1.00 (0.99
to 1.00) for 6 months, and 0.99 (0.99 to 1.00) for once every
9–12 months (see Figure S2, Supplemental Digital Content,
http://links.lww.com/QAI/A794). The corresponding esti-
mates for 18-month AIDS-free survival (95% CI) were 0.99
(0.98 to 0.99), 0.99 (0.99 to 0.99), and 0.99 (0.98 to 0.99),
respectively (see Figure S2, Supplemental Digital Content,
http://links.lww.com/QAI/A794).
Virologic Failure
Compared with monitoring every 3 months, the overall
risk ratio for virologic failure (HIV RNA .200 copies/mL) at
186 2 months (95% CI) was 0.74 (0.46 to 1.19) for 6 months
and 2.35 (1.56 to 3.54) for 9–12 months (Table 3). When
virologic failure was defined as HIV RNA .50 copies per
milliliter, the corresponding estimates were 0.64 (0.49 to
0.84) and 1.18 (0.88 to 1.59), though a cutoff of 50 was likely
less than the lower limit of detection in the earlier years of
follow-up. Alternative monitoring strategies resulted in
estimates that varied somewhat (see Table S7, Supplemental
Digital Content, http://links.lww.com/QAI/A794), but the
95% confidence intervals were wide.
CD4 Cell Count
The mean baseline CD4 cell count was 397 cells per
microliter. At 18 months, the mean CD4 cell count (95% CI)
was 506.2 cells per microliter (450.7 to 568.6) for monitoring
once every 3 months, 500.8 cells per microliter (444.7 to
564.1) for 6 months, and 474.5 cells per microliter (420.2 to
535.8) for 9–12 months (Fig. 2). The 18-month mean CD4
cell count difference (95% CI) was 25.3 (218.6 to 7.9) for
6 months and 231.7 (252.0 to 211.3) for 9–12 months,
compared with 3 months. Adjusting only for baseline
confounding resulted in similar differences (data not shown).
Excluding intravenous drug users, those with an unknown
mode of transmission, and individuals presenting late to care
resulted in larger estimates of mean CD4 cell count at 18
months in each of the 3 arms, but the ranking of the 3
strategies did not change (see Figure 3, Supplemental Digital
Content, http://links.lww.com/QAI/A794).
DISCUSSION
We found little evidence for an effect of monitoring
frequency on death or AIDS-defining illness or death in the
short term among individuals who achieve virologic suppres-
sion within 12 months of cART initiation. Our findings
suggest that monitoring every 9–12 months increases the risk
of virologic failure compared with monitoring every 3 months;
FIGURE 1. Number of individuals following each monitoring strategy over follow-up, HIV-CAUSAL Collaboration and CNICS.
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TABLE 2. Unadjusted Baseline and Time-Varying Characteristics of 10,525 Uncensored Individuals at 14 Months of Follow-up by
Monitoring Strategy, HIV-CAUSAL Collaboration and CNICS
Persons, % (n)
Overall
(n = 10,525)
Monitor Once Every
3 6 1 mo (n = 7653)
Monitor Once
Every 6 6 1 mo (n = 1886)
Monitor Once Every
9–12 6 1 mo (n = 986)
Baseline characteristic
Cohort
FHDH 21.0 (2206) 21.9 (1672) 16.7 (315) 22.2 (219)
VACS 9.7 (1019) 9.4 (718) 9.3 (175) 12.8 (126)
All others 69.3 (7300) 68.7 (5260) 64.0 (1396) 65.0 (641)
CD4 cell count, cells/mL
,200 22.8 (2404) 17.6 (1347) 29.4 (554) 51.0 (503)
200 to ,350 29.4 (3096) 33.1 (2532) 20.4 (385) 17.9 (176)
350 to ,500 27.4 (2881) 29.4 (2252) 24.3 (459) 17.2 (170)
$500 20.4 (2144) 20.0 (1519) 25.9 (488) 13.9 (137)
Mean, value 358 369 363 265
Age, yrs
,35 31.1 (3269) 30.6 (2340) 32.2 (607) 32.7 (322)
35–50 49.5 (5213) 49.6 (3799) 49.7 (938) 48.3 (476)
.50 19.4 (2043) 19.8 (1514) 18.1 (341) 19.1 (188)
Acquisition group
Heterosexual 33.6 (3536) 34.0 (2600) 30.0 (565) 37.6 (371)
Homo/bisexual 46.8 (4926) 47.4 (3627) 49.4 (931) 37.3 (368)
Injection drug user 5.1 (540) 4.7 (356) 5.7 (108) 7.7 (76)
Other/unknown 14.5 (1523) 14.0 (1070) 15.0 (282) 17.3 (171)
Calendar year
2000–2002 13.8 (1454) 14.3 (1097) 10.9 (206) 15.3 (151)
2003–2005 24.4 (2570) 26.2 (2001) 17.8 (336) 23.6 (233)
2006–2008 33.1 (3484) 34.3 (2627) 29.6 (559) 30.2 (298)
$2009 28.7 (3017) 25.2 (1928) 41.6 (785) 30.8 (304)
Months to suppression
2–4 31.4 (3304) 34.5 (2639) 20.0 (377) 29.2 (288)
5–8 50.1 (5273) 50.1 (3833) 51.8 (977) 47.0 (463)
9–12 18.5 (1948) 15.4 (1181) 28.2 (532) 23.8 (235)
Mean, value 6.0 5.8 6.9 6.3
Years since HIV diagnosis
,1 37.8 (3973) 37.7 (2886) 35.9 (677) 41.6 (410)
1 to ,5 36.7 (3861) 37.0 (2830) 39.3 (741) 29.4 (290)
5 or more 12.6 (1328) 12.8 (980) 12.7 (239) 11.1 (109)
Unknown 13.0 (1363) 12.5 (957) 12.1 (229) 18.0 (177)
Time-varying characteristic
Most recent CD4 cell count, cells/mL
,200 11.5 (1211) 6.4 (492) 19.3 (364) 36.0 (355)
200 to ,350 20.7 (2183) 21.2 (1623) 17.1 (322) 24.1 (238)
350 to ,500 27.0 (2845) 30.2 (2314) 19.8 (374) 15.9 (157)
$500 40.7 (4286) 42.1 (3224) 43.8 (826) 23.9 (236)
Mean, value 471 487 472 351
Most recent HIV RNA, copies/mL
#200 95.5 (10,048) 95.9 (7338) 96.1 (1813) 91.0 (897)
201–999 1.8 (193) 1.8 (137) 1.5 (29) 2.7 (27)
1000–9999 1.3 (133) 1.1 (87) 1.0 (18) 2.8 (28)
$10,000 1.4 (151) 1.2 (91) 1.4 (26) 3.5 (34)
Mean, value 1568 1375 922 4305
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however, the results varied according to the definition of
virologic failure.
Our estimates also suggest that monitoring every 6
months or less frequently results in lower mean CD4 cell
counts at 18 months than monitoring every 3 months (though
the 95% confidence intervals were wide). This finding might
reflect intermittent adherence among individuals monitored
less frequently. However, the mean CD4 cell count at 18
months was greater than 400 cells/ml under all of the
monitoring strategies, and so the clinical relevance of these
differences could be debated. The findings for virologic
failure and mean CD4 cell count might reflect intermittent
or poor adherence among individuals monitored less
frequently. Non-adherence has been shown to predict
virologic failure in a previous study,24 and intermittent
adherence could have a gradual effect on CD4 cell count.
Our study complements previous randomized trials10,25
and observational studies9,11–13 comparing CD4 cell count and
HIV RNA monitoring strategies, which did not assess clinical
endpoints. One randomized trial found no difference in
virologic failure after 24 months between monitoring every
4 months versus every 6 months, but results have not been
published.10 A second randomized trial in the USA compared
HIV RNA monitoring frequencies, but did not require
individuals to be virologically suppressed at entry.25
Some limitations of our study should be noted. Similar
to any other observational study, the validity of our estimates
relies on the untestable assumption that the measured
covariates were sufficient to adjust for confounding and
selection bias. If individuals monitored more frequently were
those with greater health-seeking behaviors and adherence
than those monitored less frequently, or if individuals
monitored more (or less) frequently were individuals at later
stages of HIV infection or who have been diagnosed with
comorbidities, our results would be confounded. However, an
analysis excluding individuals presenting late to care (initi-
ating cART at a CD4 cell count ,200 cells/mL) did not yield
appreciably different results. Although we were not able to
adjust for comorbidities in our analysis, time since the last
clinic visit can serve as a proxy for comorbidities under the
assumption that individuals diagnosed with comorbidities will
have more frequent clinic visits. An analysis adjusting for
time since the last clinic visit did not change our estimates.
Further, if physicians monitor individuals perceived to have
lower adherence with greater frequency, frequent monitoring
could appear to be less beneficial than it is. Excluding
subgroups of individuals hypothesized to be monitored
infrequently and have high rates of death, such as intravenous
drug users and those with an unknown mode of transmission,
did not affect the results. Some residual confounding owing to
centers within each cohort is possible. Although our effect
estimates are adjusted for cohort, we were not able to adjust
for the individual centers within each cohort.
Misclassification is possible in our study. If individuals
had CD4 cell count and HIV RNA measured but not recorded
by our cohorts, monitoring frequency will be underestimated.
With the exception of CNICS, all cohorts included in this
analysis are based on data collected from national health care
FIGURE 2. Eighteen-month mean CD4 cell curves by
monitoring strategy, HIV-CAUSAL Collaboration and CNICS.
TABLE 3. Clinical and Virologic Outcomes by Monitoring
Strategy, HIV-CAUSAL Collaboration and CNICS
Outcome and
Monitoring Strategy
Outcomes,
Cases
Person-
Months
IPW-Adjusted Hazard
Ratios (95% CI)
All-cause mortality
Monitor once every
3 6 1 mo
126 345,310 1.00 (reference)
Monitor once every
6 6 1 mo
72 208,055 0.86 (0.42 to 1.78)
Monitor once every
9–12 6 1 mo
67 189,900 0.82 (0.46 to 1.47)
AIDS-defining illness
or death
Monitor once every
3 6 1 mo
310 344,246 1.00 (reference)
Monitor once every
6 6 1 mo
197 207,446 0.76 (0.50 to 1.16)
Monitor once every
9–12 6 1 mo
183 189,353 1.06 (0.55 to 2.08)
No. Failed*
IPW-Adjusted Risk
Ratios (95% CI)
Virologic failure (RNA .200)
Monitor once every
3 6 1 mo
193 1.00 (reference)
Monitor once every
6 6 1 mo
30 0.74 (0.46 to 1.19)
Monitor once every
9–12 6 1 mo
33 2.35 (1.56 to 3.54)
*Based on 4497, 919, and 447 individuals with HIV RNA measurements at 18 6 2
months following the every 3 months, every 6 months, and every 9–12 months
strategies, respectively.
IPW, inverse-probability weighted.
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systems that offer universal access to care, and so it may be
unlikely that individuals receive laboratory monitoring out-
side of their primary clinic, particularly in more recent years.
Further, excluding CNICS from the analysis and restricting
the analysis to more recent years resulted in similar effect
estimates. Measurement error for the combined endpoint of
AIDS-defining illness or death could be possible if individ-
uals monitored more frequently have clinical events detected
sooner, but adjusting for time since the last clinic visit reduces
this bias. Finally, although AIDS-defining illnesses are
typically underreported, it is unlikely that this misclassifica-
tion would be related to monitoring frequency. Because the
mean time to event among those who had an event and the
average duration of follow-up were relatively short, we were
not able to assess survival and AIDS-free survival over
a period longer than 18 months. However, antiretroviral
therapy is lifelong and therefore we cannot draw conclusions
about the long-term impact of less frequent monitoring, which
could lead to decreases in adherence or delays in treatment
switching and as a consequence poorer clinical outcomes.
Each death and AIDS-defining illness or death contributed to
more than one monitoring strategy on average, which could
have attenuated the effect estimates. Still, 18-month estimates
may be useful in informing clinical practice. CD4 cell count
and HIV RNA were usually monitored at the same time in our
study, and so evaluating strategies where CD4 cell count and
HIV RNA are measured with different frequencies was not
possible. Finally, the cohorts included in this analysis are
from developed countries; our results may not be generaliz-
able to resource-limited settings or to other health care
systems. However, our results were robust to alternative
monitoring strategies and definitions of virologic suppression,
various functional forms of follow-up time, and in many
subgroup analyses.
In summary, our findings suggest that less frequent
monitoring of individuals on cART with confirmed
virologic suppression has little effect on clinical outcomes
by 18 months of follow-up. Because effects of different
monitoring strategies could take years to materialize,
longer follow-up is needed to fully evaluate this question.
These findings are consistent with current European and
United States guidelines regarding monitoring frequency
after cART initiation.
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